We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
Yapa® is a free social app with an emphasis on your mental health. The application gives a solution to the users to have accurate changes in both mental illness and mental wellness. The application has exceeded 10,000 downloads, and it has 400,000 followers. It has elected former England and Liverpool FC goalkeeper Chris Kirkland as the first ambassador to encourage and build Yapa. The funds will be used for marketing, operation and product innovation.
days to go: Expired investment: £41,930
WeTRAIN is a new way to have fun with personal training. They are the first shared personal training company and by doing this, they are creating a market of social exercise. WeTRAIN makes it easy for friends to have high quality, personalised training in a variety of different classes.
days to go: Expired investment: £437,138
Qure are an affordable and convenient on-demand healthcare service providing a doctor to users doors within 2 hours, 24/7. The hassle-free healthcare connects individuals with highly-experienced medical practitioners in the local area. 
days to go: Expired investment: £720,000
Riders can enjoy indoor cycling within a boutique fitness studio. In the past 6 years, Boom Cycle have opened five sites are now seeking funds to expand their portfolio. To date, Boom Cycle has acquired over £4.1m from private investors and in 2017 spent £2.1m on developing two flagship studios. The company has experienced attendance growth of 47% YoY, as well as a 77% increase in revenue YoY.
days to go: Expired investment: £805,260
PathCloud aims to assemble the global clinical diagnostics resources and data and make them safely available and helpful. The company has created and tested one of the first scalable clinical diagnostics management platforms. It currently has 20,000 clinicians partner networks and 92 registered clinicians. Additionally, it has a network across 48 counties, has over 100 providers, over 3500 diagnostics tests registered and over 10,000 patients by partner telemedicine networks. These funds will be used to gain a significant portion of diagnostics supplier agreements towards the scaling objective, increase efforts towards the international markets and NHS and pursue telemedicine networks.
days to go: Expired investment: £81,720
Next-generation wellbeing analytics for individuals and organisations – boosts happiness and productivity
days to go: Expired investment: £768,597
Rightangled is a healthcare technology company backed by NHS England & regulated by the Care Quality Commission (CQC). It began its journey as a platform that would enable the use of genetic information within the medical practice, in an accurate, streamlined, and affordable way. It gradually established itself as a healthcare provider for screening and diagnostic services. Its Heart DNA Test project, launched in 2017, is helping patients minimize their cardiac risks and enabling doctors to have a complete risk profile for their patients. The project was appreciated and received funding from NHS England. Its next project, Fitness DNA Test, tapped into the fitness and wellbeing markets. Recently, in the wake of the COVID-19 threat, the company has developed a home-based throat swab test to detect the viral infection, by testing viral load presented in its nucleic acid material within (RNA). For its efforts, Rightangled has been featured on CNN, Sky News, LBC radio, Sky News radio, and Newsweek. With the investment, the company aims to release a mobile application by the end of 2020, and develop an AI system to give instant tailored health, diet, and fitness advice to its users based on the data gathered from patient-doctor interactions and patient responses.

Pitch Rated

81%

Gold

rating powered by

CROWD RATING™

days to go: Expired investment: £522,689
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph